key dates from a clear mind:
we have important catalysts with known timelines.
if you wanna take a chance sharing CYDY with a friend now is the time.
tnbc data showed the PD-1 expression MOA.
that data was strong and consistent.
mss-crc data from years ago was "good". that's as far as i'll go on that scant data.
every cancer is different, but i do believe there will be strong PD-1 impact again.
they submitted abstracts early to make the deadlines for the biggest cancer conferences.
we have those dates.
we can see the AACR abstract title on the 17th
it seems to me that they are doing PD-1 at ACCR and tumor shrinkage at ASCO.
we also know when the PRs will occur
AACR is april 17 thru 22 ASCO may 29-jun 2.
PRs will occur day of or day after cytodyn presents.
now is the time for new folks to take a shot with CYDY.
price is contained but that might not last.
other initiatives could have updates soon.
there could be a share price move prior to the conferences.
the downside, even near term, seems to be quite limited.
people should have no fear of an entry while the share price remains contained.
THE CHART! quite a busy chart.
1)
there is a daily descending trend line that has been in play for the entire lifetime of the stock. the price failed the wedge somehow, but recovered it and looks primed to test that trend line for the 3rd time this year as the wedge bottomed at .21 closes. the wedge is a mere 2 and a half cents now.
2)
it has an daily ascending trend line, almost a year old and you could argue for further back than that. the descending and ascending daily trend lines are just about to cross in the next couple trading days, 5 cents above the .21 support.
when it breaks that trend line it has new life. its like being stuck at the bottom of a well for a long time and finally finding a way over the top. doesn't mean it will blast up, but it will at least no longer have that age old descending trend line holding it down.
.39 has a big target on its back like a "kick me" sign, begging for attention at some point.
3)
there's also a weekly ascending trend line about to cross the 3 year high around .50 and above there sits the cover on top of the boiling pot at .54. you have a stretch from .39 to .54 that could trap the action for a bit. above .54 is where you get into the blue sky zone. or is it "open waters"?
this is just the type of post that i have lambasted for 5 years now. but the time has come folks. NO BULLSHIT BREAD CRUMBS. no fantasy role play. just clinical evidence and hugely important imminent catalysts of tremendous potential value and its all very reasonably de-risked imo.
given the history of this thing, i am at a loss to guess whether there will be a significant bump after these conferences. the "biomarker" abstract is not at all the type of thing traders typically get excited about. they want OUTCOMES. and even thought this particular biomarker data is oddly just as important or even much more important than "outcomes" data, i'm not how many buyers will have any awareness of that.
having the aprril and then may releases coming close together is a big big plus for having the momo traders fully engaged at the end of may.
trust me when i say i have been widely despised on these boards for years. lol i know its not too hard to imagine! but anyway, i think we're all on the same side now, more or less.
we have important catalysts with known timelines.
if you wanna take a chance sharing CYDY with a friend now is the time.
tnbc data showed the PD-1 expression MOA.
that data was strong and consistent.
mss-crc data from years ago was "good". that's as far as i'll go on that scant data.
every cancer is different, but i do believe there will be strong PD-1 impact again.
they submitted abstracts early to make the deadlines for the biggest cancer conferences.
we have those dates.
we can see the AACR abstract title on the 17th
it seems to me that they are doing PD-1 at ACCR and tumor shrinkage at ASCO.
we also know when the PRs will occur
AACR is april 17 thru 22 ASCO may 29-jun 2.
PRs will occur day of or day after cytodyn presents.
now is the time for new folks to take a shot with CYDY.
price is contained but that might not last.
other initiatives could have updates soon.
there could be a share price move prior to the conferences.
the downside, even near term, seems to be quite limited.
people should have no fear of an entry while the share price remains contained.
THE CHART! quite a busy chart.
1)
there is a daily descending trend line that has been in play for the entire lifetime of the stock. the price failed the wedge somehow, but recovered it and looks primed to test that trend line for the 3rd time this year as the wedge bottomed at .21 closes. the wedge is a mere 2 and a half cents now.
2)
it has an daily ascending trend line, almost a year old and you could argue for further back than that. the descending and ascending daily trend lines are just about to cross in the next couple trading days, 5 cents above the .21 support.
when it breaks that trend line it has new life. its like being stuck at the bottom of a well for a long time and finally finding a way over the top. doesn't mean it will blast up, but it will at least no longer have that age old descending trend line holding it down.
.39 has a big target on its back like a "kick me" sign, begging for attention at some point.
3)
there's also a weekly ascending trend line about to cross the 3 year high around .50 and above there sits the cover on top of the boiling pot at .54. you have a stretch from .39 to .54 that could trap the action for a bit. above .54 is where you get into the blue sky zone. or is it "open waters"?
this is just the type of post that i have lambasted for 5 years now. but the time has come folks. NO BULLSHIT BREAD CRUMBS. no fantasy role play. just clinical evidence and hugely important imminent catalysts of tremendous potential value and its all very reasonably de-risked imo.
given the history of this thing, i am at a loss to guess whether there will be a significant bump after these conferences. the "biomarker" abstract is not at all the type of thing traders typically get excited about. they want OUTCOMES. and even thought this particular biomarker data is oddly just as important or even much more important than "outcomes" data, i'm not how many buyers will have any awareness of that.
having the aprril and then may releases coming close together is a big big plus for having the momo traders fully engaged at the end of may.
trust me when i say i have been widely despised on these boards for years. lol i know its not too hard to imagine! but anyway, i think we're all on the same side now, more or less.
7
